Abstracts tagged "giant cell arteritis"

Abstract Number: 861 • 2016 ACR/ARHP Annual Meeting
Efficacy of Methotrexate in Giant Cell Arteritis
Matthew J. Koster¹, Cynthia S. Crowson², Cristian Labarca³, Francesco Muratore⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ⁴Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Prospective trials evaluating methotrexate (MTX) as adjunct immunosuppression in giant cell arteritis (GCA) have provided evidence of a modest benefit for reducing risk of…
Abstract Number: 2074 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster and the Risk of Incident Giant Cell Arteritis
Bryant R. England¹, Ted R. Mikuls², Fenglong Xie³, Shuo Yang³, Lang Chen³ and Jeffrey Curtis⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Antigenic triggers initiating granulomatous inflammation in giant cell arteritis (GCA) have yet to be elucidated. Recently, histopathological studies of temporal arteries from GCA patients…
Abstract Number: 862 • 2016 ACR/ARHP Annual Meeting
Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Sara Alehashemi¹, Mark Ahlman², Ali Cahid Civelek², Elaine Novakovich³, Ashkan Malayeri², Peter A. Merkel⁴, Thomas Cupps⁵, David Bluemke² and Peter C. Grayson³, ¹Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁵Rheumatology, Georgetown University, Bethesda, MD
Background/Purpose: FDG-PET may have a role in diagnosing and monitoring disease activity in large vessel vasculitis (LVV). Studies that assess the diagnostic accuracy of PET…
Abstract Number: 2077 • 2016 ACR/ARHP Annual Meeting
Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis
Jocelyn Ma^1,2, Nader A. Khalidi³, Ola Wierzbicki², Abdallah Al Qethami⁴, Simon Carette⁵ and Christian Pagnoux⁶, ¹Department of Family Medicine, University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁴Internal Medicine/Adult Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Few retrospective studies in giant cell arteritis (GCA) previously reported, separately, that 1) patients with diabetes had less positive temporal artery biopsies (TAB), 2)…
Abstract Number: 865 • 2016 ACR/ARHP Annual Meeting
Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis
Claire Le Pendu¹, Véronique Meignin², Solange Gonzalez-Chiappe³, Françoise Galateau-Sallé⁴ and Alfred Mahr³, ¹Internal Medicine, Hospital Saint Louis, PARIS, France, ²Pathology, Saint Louis Hospital, PARIS, France, ³Internal Medicine, Hospital Saint-Louis, Paris, France, ⁴Pathology, Caen Hospital, Caen, France
Background/Purpose: Histological findings of intima-media or transmural inflammation in temporal artery biopsies (TABs) have undisputed high value for diagnosis of giant cell arteritis (GCA). Conversely,…
Abstract Number: 2151 • 2016 ACR/ARHP Annual Meeting
Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA
Marc Corbera-Bellalta¹, Ester Planas-Rigol², Nekane Terrades-Garcia¹, Marco Antonio Alba¹, Georgina Espígol-Frigolé², Sergio Prieto-González², Jose Hernández-Rodríguez¹ and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: The development of giant-cell arteritis (GCA) lesions requires amplification cascades resulting in continuous recruitment of lymphocytes and monocytes. Interferon-gamma (IFNg)- induced or up-regulated chemokines…
Abstract Number: 866 • 2016 ACR/ARHP Annual Meeting
Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?
Yousef Zarbalian¹, Kimberly P. Liang², Ronald L. Hamilton³, Li Wang⁴ and Dan Winger⁵, ¹Medicine, Division of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Pathology, Division of Neuropathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Office of Clinical Research, University of Pittsburgh, Pittsburgh, PA, ⁵Office of Clinical Research, Health Sciences, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The diagnosis of giant cell arteritis (GCA) by temporal artery (TA) biopsy requires pathologic identification of arterial inflammation, usually with giant cells. However, some…
Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster² and Kenneth J. Warrington³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…
Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger⁴, Diana Dan⁴, Michael Seitz⁴ and Peter M. Villiger⁴, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, ⁴Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose:
Abstract Number: 3044 • 2016 ACR/ARHP Annual Meeting
Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis
Ester Planas-Rigol¹, Nekane Terrades-Garcia², Marc Corbera-Bellalta², Ester Lozano², Marco Antonio Alba², Georgina Espígol-Frigolé³, Sergio Prieto-González², Marta Segarra², Jose Hernández-Rodríguez², Sara Preciado⁴, Rodolfo Lavilla⁴ and Maria C. Cid², ¹Vasculitis research unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Vasculitis Research Unit, Systemic Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Laboratory of Organic Chemistry, Faculty of Pharmacy. Barcelona Science Park, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is a vascular inflammatory disease involving large and medium sized arteries, particularly the cranial vessels. Inflammation-induced vascular remodeling leads to…
Abstract Number: 873 • 2016 ACR/ARHP Annual Meeting
Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Richard Conway¹, Karen Creevey², Michelle Trenkmann³, Geraldine M. McCarthy⁴, Conor Murphy⁵, Douglas J. Veale⁶, Ursula Fearon⁷ and Eamonn S. Molloy⁸, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²St. Vincent's University Hospital, Centre for Athritis and Rheuamtic Diseases, Dublin Academic Medical Centre,, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁴Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁷Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. The pathogenesis of GCA remains incompletely understood. Current evidence suggests that dendritic…
Abstract Number: 3182 • 2016 ACR/ARHP Annual Meeting
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Berit Dalsgaard Nielsen¹, Ib Tønder Hansen², Kresten Krarup Keller³, Philip Therkildsen⁴, Ellen-Margrethe Hauge³ and Lars Christian Gormsen⁵, ¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ⁵Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark
Background/Purpose: Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT is, due to its excellent diagnostic accuracy[1], increasingly used to diagnose large vessel GCA (LV-GCA). However, PET/CT is not always readily…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Stephan Reichenbach^1,2, Sabine Adler³, Jennifer Cullmann⁴, Harald Bonel⁴, Stefan Kuchen⁵, Felix Wermelinger¹, Diana Dan¹, Michael Seitz¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ⁴Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger², Diana Dan², Peter M. Villiger² and Michael Seitz², ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].